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Background: Although new approaches to the treatment of patients with cystic fibrosis (CF) are significantly prolonging their lives, most
patients will eventually develop respiratory failure due to progressive bronchiectasis caused by chronic lung infection and inflammation and
die from to respiratory failure. We examined our center's (University of Wisconsin Hospital and Clinics) experience with lung transplantation
for patients with CF and reviewed the literature to examine current and evolving approaches to transplantation for this indication.
Methods: We reviewed all published literature pertaining to lung transplantation for CF through 2006, and we reviewed all aspects of
transplantation for patients with CF at our institution from 1994 to 2005.
Results: Major complications following lung transplantation include acute rejection, bacterial infection, and bronchiolitis obliterans. Five-
year survival at UWHC (Kaplan–Meier) is 67%, and survival was not adversely affected by transplanting patients receiving mechanical
ventilation. The major cause of death for transplant recipients was bronchiolitis obliterans syndrome (BOS).
Conclusions: Lung transplantion for CF is associated with acceptable survival rates and can improve quality of life. Lung transplant should
be offered to all patients with advanced CF lung disease if they meet currently accepted inclusion and exclusion criteria.
© 2007 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic fibrosis; Lung transplantation; Thoracic surgery1. Introduction
Lung transplantation has become a treatment option for
progressive respiratory failure in patients with cystic fibrosis
(CF). Although advances in monitoring and medical
treatment for CF have progressively extended life expectan-
cy over the past few decades such that the majority of
patients with CF will reach adulthood, nearly all patients
with severe disease will eventually develop advanced⁎ Corresponding author. Section of Allergy, Pulmonary, and Critical Care
Medicine, Department of Medicine and Section of Pediatric Pulmonology,
Department of Pediatrics, United States.
E-mail address: jonathan.spahr@chp.edu (J.E. Spahr).
1569-1993/$ - see front matter © 2007 European Cystic Fibrosis Society. Publish
doi:10.1016/j.jcf.2006.12.010bronchiectasis and have sustained decline in lung function
to the point that lung transplantation becomes the only option
for improved quality of life and survival [1,2]. This will
undoubtedly continue to be the case for the next few decades
until therapies that prevent progressive lung disease and
respiratory failure become available. Although the number
of potential recipients listed for transplantation has grown
considerably, the supply of donor lungs has remained
relatively limited. Because there is a discrepancy between
organ need and availability, issues related to transplant
candidacy, contraindications to transplant, timing of trans-
plantation, and post-transplant complications are of para-
mount importance to successfully prolonging the lives of CF
patients with lung transplantation. To optimize the utilizationed by Elsevier B.V. All rights reserved.
Table 1
Determinants of the lung allocation score
⋅ Disease indication for lung transplant
⋅ Forced vital capacity (% predicted)
⋅ Pulmonary arterial systolic pressure
⋅ Supplemental oxygen requirement (L/min)
⋅ Age
⋅ Body mass index
⋅ Insulin-dependent diabetes
⋅ Functional status (NYHA class)
⋅ Six-minute walk test (6-MWT) distance
⋅ Ventilator use
⋅ Pulmonary capillary wedge pressure
⋅ Serum creatinine
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accurately determine which patients at what point in the
course of their progressive lung disease would benefit most
from lung transplantation. Although lung transplantation is
relatively novel, many of these issues have now been
intensively investigated. Twenty years of lung transplanta-
tion for CF has provided CF caregivers with many important
lessons about this potentially life-extending procedure, and
lung transplantation has become a standard of care option for
patients with end-stage lung disease due to CF if they meet
eligibility criteria.
In 2005 the International Society for Heart and Lung
Transplantation (ISHLT) presented data on lung transplan-
tation up until June 2004 [3]. The total number of lung
transplantations registered from 1985 to June 2004 was
19,197. From January 1995 to June 2004, 2153 (17%) of the
adults who received lung transplants had CF. Of the children
who had lung transplants for various indications, 37% of
those who were 1–10 years of age received lung transplants
for CF, as did 72% of children ages 11–17 years old (data for
January 1991 to June 2004). Interestingly, the proportion of
total transplants performed for CF has remained constant
while the proportion of transplants for emphysema has
gradually increased. According to the international registry,
five-year survival for adults transplanted for CF worldwide
since 1994 is about 50% [3]. In all lung transplants, one-year
survival is approximately 75%, five-year survival is nearly
50% and long-term survival is approximately 25% at
10 years [3]. In subsequent sections pertaining to complica-
tions it will become evident why these mortality statistics are
relatively poor when compared to survival statistics for other
transplanted organs.
This manuscript reviews what has been learned over the
past 2 decades of lung transplantation for CF and examines
salient aspects of lung transplantation for patients with CF at
the University of Wisconsin Hospital Center (UWHC) who
underwent cadaveric bilateral lung transplantation from 1994
to 2005. Important issues include pre-transplant considera-
tions such as eligibility criteria for transplantation, contra-
indications to lung transplantation, and preparation for the
transplant procedure. We will review surgical techniques and
complications, post-transplantation issues including surveil-
lance for infection and rejection, immediate and long-term
complications, current approaches to immunosuppression,
and outcome. We will also discuss special issues that pertain
to lung transplantation in children with CF and issues that are
specific for pediatric lung transplant candidates.
1.1. Pre-transplantation issues
1.1.1. Criteria for transplantation
Approximately 20–30% of CF patients die of progressive
lung disease while awaiting lung transplantation [4].
Because only a limited number of organs are available, it
is clear that one of the most difficult issues surrounding
transplantation is when to refer a patient for transplantation.The decision to refer a patient with cystic fibrosis for lung
transplantation should occur when expected survival without
transplantation is likely to be shorter than expected survival
after transplantation. After dissecting out the determinants of
expected survival, one realizes that such a decision is by no
means simple or straightforward. Most authorities have
recommended that referral should occur when expected
survival slightly exceeds the time that a patient would spend
waiting for a lung transplant. In the past, when the lung
allocation system was prioritized according to time spent on
the list, this waiting time had generally been 6 months to
2 years. The mean waiting time from listing to transplanta-
tion at our center was 14.5±10.4 months under this system.
In April of 2005, the United Network for Organ Sharing
(UNOS) adopted a new allocation system for individuals
older than 12 years of age [5]. This new allocation system
currently in use in the United States (Table 1) applies clinical
data to generate a lung allocation score that, in combination
with ABO blood group compatibility and thoracic dimen-
sions, determine which lung transplant candidate will be first
in line when matching organs are offered to the transplant
center. This new system was devised to allow more effective
allocation of organs to those candidates who are most in need
of transplantation. Since it has just recently been implemen-
ted, data pertaining to waiting time on the transplant list is
not yet available however, preliminary data suggest that
there are fewer individuals, including those with CF, who die
while on the waiting list [6]. Despite this change in choosing
candidates for lung transplantation, the issue of what
constitutes the ideal time to refer an individual for lung
transplantation remains somewhat controversial. There have
been many recommendations as to what constitutes severe
enough disease that would predict early mortality if a patient
does not undergo lung transplantation. Criteria for referral
that are currently accepted by most CF Centers are given in
Table 2.
Kerem et al. published data in 1992 to suggest
that FEV1% less than 30% predicted, PaCO2 N50 mm
Hg and PaO2b55 mm Hg altogether were associated with
a 2-year mortality of approximately 50% [7]. Others have
taken these findings, defined as progressive lung function
Table 2
Referral criteria for lung transplantation for cystic fibrosis
• Progressive pulmonary function impairment
▪ FEV1 b30% predicted
▪ Severe hypoxemia (PaO2 b55 mm Hg)
▪ Hypercarbia (PaCO2 N50 mm Hg)
• Increasing functional impairment
▪ Increasing frequency of respiratory exacerbations requiring antibiotic
therapy
▪ Exacerbation of pulmonary disease requiring intensive care unit stay
• Major life-threatening pulmonary complications
▪ Rapidly progressive respiratory failure
▪ Massive/recurrent hemoptysis not controlled by embolization
▪ Refractory and/or recurrent pneumothorax
▪ Rapidly progressive cachexia
• Rapid decline in FEV1 (especially young females)
Table 3
Pre-transplant characteristics of recipients with CF transplanted at UWHC
(N=57)
Mean age 32.4±8.0
Male:female 33:24
Mean FEV1 (% predicted) (N=53) 24.8±7.9
Mean body mass index (BMI) 19.4±3.2
Mean wait time while listed (months) 14.5±10.4
Supplemental oxygen-dependent 50 (87.7%)
BIPAP-dependent 18 (31.6%)
Required mechanical ventilation (MV) a 12 (21.1%)
Transplanted while receiving MV 10 (17.5%)
Tracheostomy 10 (17.5%)
Gastrostomy feeding tube 20 (35.1%)
CF-associated diabetes 22 (38.6%)
Osteoporosis (N=46) 12 (21.5%)
Pan-resistant P. aeruginosa 1 (1.8%)
Methicillin-resistant S. aureus 3 (5.3%)
All patients underwent bilateral lung transplant. Mean values are reported
with standard deviations.
a Seven of the patients who received mechanical ventilation were
originally ventilated with BiPAP.
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functional impairment, increasing number of respiratory
exacerbations, major life-threatening complications (e.g.
hemoptysis and pneumothorax), and increasing antibiotic
resistance to help determine an increased probability of
mortality without intervention with lung transplantation
[1]. Flume et al. have shown data that demonstrates
massive hemoptysis and pneumothorax are two complica-
tions of CF that significantly increase 2-year mortality
regardless of lung function [8,9]. Liou et al. [10] proposed
a more predictive model using age, gender, FEV1%,
weight-for-age, pancreatic sufficiency, diabetes mellitus,
the presence of S. aureus or B. cepacia infection, and the
number of respiratory exacerbations to calculate probabil-
ity of survival. This more predictive model was proposed
because data from the Cystic Fibrosis Foundation Patient
Registry indicated that patients who had received a lung
transplant had a significantly lower 5-year survival than
matched controls, and FEV1% less than 30% by itself did
not appear to be an accurate predictor of patients who
would have an improved post-transplant survival [11]. The
patient characteristics used by this model appeared to more
accurately predict a survival benefit for recipients listed
according the criteria used by Liou et al.
Special consideration may be warranted for younger
individuals with rapid lung function decline, especially
females. Robinson and Waltz [12] recommend earlier
referral for young patients with FEV1% falling below
50%, and International Guidelines published in 1998
indicate that young females with rapidly deteriorating lung
function should be referred for transplant regardless of
physiologic criteria given the poor prognosis that has been
identified for this group of CF patients [13]. Other factors
such as life-threatening hemoptysis may prompt a referral for
lung transplantation as well, and some investigators have
examined the use of cardiopulmonary exercise testing
(CPET) to determine the severity of lung disease in CF
[14–16]. Tantisira et al. [17] have identified the CPET
breathing reserve index at lactate threshold as a predictor of
mortality for those considering lung transplantation.Data from our own institution indicate that patients
exclusively treated at our CF center with an FEV1% less than
30% and who had not been transplanted had a 74% survival
in 2 years and 67% in 5 years, and the long-term survival did
not differ for transplanted versus non-transplanted patients
[18]. Our experience and that of many other transplant
centers suggest that the decision to refer is quite complicated
and not easily reached for many patients. The fact that the
percentage of lung transplants for CF has remained relatively
stable worldwide, while other diseases like emphysema have
had an increase in the number of transplants, raises a number
of important questions as well. Are relatively less CF
patients being referred for transplantation because of the
advances in medical treatment of the disease? Have CF
centers become more adept at identifying patients for whom
transplant will improve survival? With new information such
as that presented by Liou et al. [10,11] and further
recommendations for timing of transplantation, it may now
be possible to better identify individuals for whom
transplantation will truly extend life and better utilize both
health care resources and the limited number of organs
available for transplantation. Additionally, the newly
implemented lung allocation scoring system adopted by
UNOS in 2005 is changing our approach to lung
transplantation and should help transplant centers make
important decisions concerning evaluation and listing of
potential candidates for lung transplant.
Patients who received lung transplants at our center had a
mean age of 32 years, and all had advanced respiratory
failure (Table 3). Nearly all patients were using continuous
supplemental oxygen, and 40% of this cohort required
assisted ventilation: invasive mechanical, 12 patients, or bi-
level positive airway pressure (BiPAP), 18 patients. Of the
12 who required mechanical ventilation, 7 were originally
ventilated with BiPAP. Nutrition was a significant issue for
the majority of patients. The mean body mass index was
Table 4
Contraindications to lung transplantation [128]
• Medical, non-infectious
▪ Absolute:
· Malignancy within 2 years
· Untreatable advanced dysfunction of another major organ system
· Significant chest wall and/or spinal deformity
· Significant left ventricular cardiac dysfunction
▪ Relative or center-specific:
· Critical or unstable condition
· Mechanical ventilation
· Significant liver dysfunction or portal hypertension
· Renal insufficiency
· Diabetes mellitus with end-organ damage
· Severely limited functional status with poor rehabilitation potential
(e.g. inability to ambulate)
· Osteoporosis (bone density below fracture threshold or symptomatic
fractures)
· Other systemic disease that would compromise long-term survival
· Suboptimally treated serious medical condition
· Severe malnutrition (BMI b18 kg/m2)
· Severe obesity (BMI N30 kg/m2)
• Medical, infectious
▪ Absolute:
· Non-curable chronic extrapulmonary infection
— HIV infection
— Hepatitis B with positive surface antigen
— Hepatitis C with biopsy-proven liver disease
· Active tuberculosis
▪ Relative or center-specific:
· Mycobacterium avium-intracellulare
· Mycobacterium abscessus
· Multiply antibiotic-resistant Pseudomonas
· Burkholderia cepacia
· Methicillin-resistant Staphylococcus aureus (MRSA)
· Aspergillus fumigatus
· Colonization with other highly resistant or highly virulent microorganisms
• Psychosocial
▪ Absolute:
· Psychiatric illness that precludes adherence to required medical
regimen
· Inability to adhere to complex medical treatment plan
· Lack of adequate social support system
· Substance addiction within previous 6 months
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Other significant problems included CF-related diabetes and
osteoporosis.
1.1.2. Contraindications to transplantation
Absolute contraindications for lung transplant vary and
have changed over the years with more experience.
However, severe extra-pulmonary disease, use of tobacco
or alcohol, impaired functional status that limits ambulation
and psychosocial problems are important issues that
generally preclude an individual from receiving a lung
transplant and having a reasonably good chance of long-term
post-transplant survival [1,13]. Contradications for lung
transplantation are listed in Table 4.
Factors that are usually considered relative contraindica-
tions and often vary from center to center relate to infection
(addressed in the subsequent section), disease severity, and
factors that may make the procedure technically difficult.
Severe malnutrition is seen by some to be a relative
contraindication to lung transplantation, and ideal body
weight b70% predicted has been associated with increased
morbidity and mortality after transplant [19]. Some experts
view chronic steroid use greater than 20 mg of prednisone
daily as a contraindication to transplantation and recommend
tapering such therapy to lower maintenance levels prior to
listing. Factors that may make the surgical technique more
challenging and that potentially preclude transplantation
include severe pleural scarring or mediastinal distortion from
previous surgery and severe kyphoscoliosis. Potential
recipients must recognize that these are very important risk
factors that may prevent a successful outcome following
transplantation.
The need for invasive mechanical ventilation is an
additional issue that has excluded patients from transplan-
tation at some centers. At our center and others, invasive
mechanical ventilation has not been considered to be a
contraindication for lung transplantation in CF [20].
Mechanically ventilated patients with CF have had satisfac-
tory long-term outcomes at our center (Fig. 1), and short-
term outcomes for patients with various indications for lung
transplantation have been shown to be similar between
mechanically ventilated and non-mechanically ventilated
patients undergoing lung transplant at other centers [21–23].
Non-invasive positive pressure ventilation has been used as a
“bridge” to transplant in patients with severe respiratory
insufficiency as a means to try and avoid invasive ventilation
and improve oxygenation both acutely and on a chronic basis
[24–27], and we have used non-invasive ventilation (BIPAP)
to support many of our patients until they could undergo
transplantation.
1.1.3. Infection and lung transplantation
Certain infections (human immunodeficiency virus,
active hepatitis B and active tuberculosis) preclude patients
from receiving a lung transplant. There are other infections
that are specific to CF that may play a role in peri-operativeand post-operative morbidity and mortality. Differences
occur among transplant centers as to which infections are
contraindications for transplantation.
Multi-resistant Pseudomonas aeruginosa is not a contra-
indication for transplantation although pan-resistant
P. aeruginosa is considered, at some centers, to be a contra-
indication. However, there are data to support transplantation
for patients even with pan-resistant P. aeruginosa. In fact,
several studies have shown no difference in post-transplant
survival between patients infected with pan-resistant
P. aeruginosa and those with sensitive bacteria [28–30].
In vitro sensitivities of P. aeruginosa may not accurately
reflect in vivo sensitivity and should be interpreted with
caution as some individuals have been shown to clinically
improve despite the use of anti-pseudomonal antibiotics that
were apparently ineffective according to in vitro sensitivites
[31]. Antibiotic synergy studies can be performed in patients
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antibiotics that may be effective in vivo [32]. Furthermore,
the use of aerosolized colistin has been shown to cause a re-
emergence of sensitive P. aeruginosa in some CF patients
awaiting lung transplantation [33].
Burkholderia cepacia can cause chronic infection in
patients with CF and is viewed by some to be a
contraindication to lung transplantation. Aris et al. [34]
published retrospective data from 121 patients with CF
showing that six month mortality was significantly increased
from 12% to 33% if chronic infection with genomovar III of
B. cepacia was present. These data suggest that determining
the specific B. cepacia genomovar may be useful in
weighing the risk of lung transplantation for patients who
grow B. cepacia.
Aspergillus fumigatus is very commonly isolated from
respiratory secretions of patients with CF [35,36]. Surpris-
ingly, this fungus rarely causes serious infections in lung
transplant recipients with CF despite post-transplant immu-
nosuppression. If Aspergillus infection does occur in
transplant patients it is usually in the form of tracheobron-
chial aspergillosis in the allograft bronchial epithelium just
distal to the anastomoses, as the injured, ischemic epithelium
is susceptible to infection when it undergoes repair following
reperfusion [35,36]. Allergic bronchopulmonary aspergillo-
sis in patients with CF following transplant has been
described, but is exceedingly rare [37,38].
While not as common as Aspergillus, Scedosporium
apiospermum is a filamentous fungus that can be isolated
from the lungs of patients with CF and may have a role in
promoting an inflammatory host response [39]. Tamm et al.
reported in 2001 the implications of Scedosporium infection
in the post-transplant period [40]. In this report, all of the
patients with Scedosporium showed airway problems,
mostly bronchiolitis obliterans. This organism has the
potential to disseminate and cause invasive disease and soFig. 1. Survival for CF patients receiving lung transplasuppressive antifungal therapy should be considered in those
who are colonized. Eradication of the Scedosporium is quite
difficult.
Non-tuberculous mycobacteria infections, specifically
M. abscessus, are being increasingly identified in patients
with CF. The potential for considerable morbidity and
mortality from this organism is not insignificant in the post-
operative period. Case reports and reports of surveys have
described the spectrum of M. abscessus disease in the
patient with CF [41,42]. In an international survey of 30
centers by Chernenko et al, the authors reported on 5510
lung transplants. Two patients were colonized prior to
transplant, and they found an incidence of 0.27% in the
post-transplant period. The reported mortality of those with
M. abscessus infection in the post-transplant period was
53.3% (8 of 15), although the authors stated that death was
at least partially attributed to infections with other
organisms or bronchiolitis obliterans [42]. In our cohort,
5 of 55 patients (9.1%) who survived the peri-operative
period had positive mycobacterial cultures. One of these
five died of complications of a bronchial anastomosis
dehiscence. This patient had Aspergillus infection of the
anastamosis. The degree of morbidity from mycobacterial
disease in lung transplant recipients varies and infection
with such organisms, especially the rapid-growers like
M. abscessus, should raise awareness about potential com-
plications. Chalermskulrat et al. recently published their
experience with non-tuberculous mycobacterial disease in
their patients with CF and lung transplantation [43]. What
this group found was that invasive mycobacterial disease in
the post-transplant period was small and attributed only to
M. abscessus. The patients were successfully treated and
mycobacterial disease did not affect the post-transplant
course. Our belief is that infection with mycobacterium is
not a contraindication to transplantation, however this view
is not shared at all centers.ntation at UW — February 1994 to April 2005.
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When considering transplantation, an extensive work-up
must be undertaken to identify factors that could preclude a
successful transplant outcome or factors that need attention
prior to referral for such a procedure. Each transplant center
has its own set of inclusion/exclusion criteria based upon
international guidelines plus the experience of the center
itself. Tests that should be obtained in order to determine
eligibility include full pulmonary function testing, electro-
cardiogram and stress echocardiogram, high-resolution
computed tomogram of the chest (HRCT), 24-hour creati-
nine clearance, and liver function tests (Table 5). A team of
physicians, nurse specialists, psychologists, and social
support workers are usually involved in this evaluation,
and all are likely to provide valuable input into the decision
for transplantation and what should be done to optimize care
prior to the referral for transplant.
In preparing for lung transplantation, the physician caring
for the CF patient must optimize care by identifying and
treating infections and ensuring that needed immunizations
are given and up to date. A tuberculosis skin test should be
administered and varicella and hepatitis B series should be
given to the patient as well as routine immunizations if the
patient is not already immune. Whether sinus infection
should be treated and to what extent is a matter of
controversy. Some centers perform endoscopic sinus surgery,
if indicated. However, there are no data that strongly support
such an approach, and medical management may be
sufficient [44–46]. Optimizing nutrition is important for
both enhancing the ability of patients to cope with their
chronic disease and in preparing patients for surgery. If
needed, we have provided supplemental nutrition by way of
gastrostomy tubes to improve calorie intake, prevent weight
loss, and facilitate weight gain. As previously stated, non-
invasive ventilation (BiPAP) may be necessary as a bridgingTable 5
Pretransplant evaluation
General Infection-specific
Full pulmonary function tests Quarterly respiratory tract cultures
Standardized exercise test (e.g. 6-
minute walk test)
Gram-negative bacilli
Electrocardiogram Methicillin-resistant S. aureus
Stress echocardiogram Mycobacteria
High-resolution CT scan of thorax Fungi
Peripheral blood cell survey Serology
Glucose and hemoglobin A1C HIV
24-hour creatinine clearance Hepatitis B and C
Bone mineral density scan Varicella
Psychological evaluation Cytomegalovirus
Toxoplasmosis
Vaccinations
PPD skin test
Evaluation and therapy of paranasal
sinus diseasetherapy to transplant to improve oxygenation and may allow
the patient to avoid invasive mechanical ventilation.
Finally, the patient must understand the risks, benefits and
alternatives to the transplant procedure. The physician must
present not only the medical implications, but also financial
and social implications that arise with lung transplantation.
Parents, spouses, relatives, and significant others should be
involved in conversations pertaining to transplantation, and
references should be available to provide more information,
should the patient need it.
2.1. Surgical issues
2.1.1. Procedure options
The ideal characteristics of the transplant donor include
verified brain death, age less than 55, smoking history less
than 20 pack-years, clear chest radiograph, PaO2:FiO2 ratio
≥300 while on 100% FIO2 and positive end-expiratory
pressure of 5 cm H2O, no chest trauma or previous surgery
on the side of lung harvest, no aspiration or sepsis, no
purulent secretions when airways are inspected via
bronchoscopy, and respiratory secretions that are negative
for bacteria or fungi and that lack large numbers of white
blood cells. Unfortunately, not all donors meet these
criteria, and compromises are frequently made to provide
organs for those who are in dire need. Additional
compromises may be made in the size matching of donors
and recipients, accepting non-heart-beating donors, and
performing single lung transplantation with contralateral
pneumonectomy.
Cadaveric transplantation has been the standard surgical
option since the inception of lung transplantation and can be
performed in a variety of ways. Single lung transplantion can
occur with one donor supplying lung tissue for two
recipients. This procedure is not as favorable as the bilateral
lung transplant that is typically performed for patients with
CF, because leaving behind an infected lung is likely to
compromise the outcome of the procedure. Creative
measures have been taken in some cases in which a single
lung may be split into 2 lobes for a smaller recipient, but this
situation is rare.
Because of the limited availability of organs and the
increased need, a second surgical option is currently
available at some centers and involves living donors. This
procedure was initially performed on critically ill recipients
as a final effort when other options appear unlikely to
occur, and it usually requires that the recipient be related to
the donors and have a thoracic cage small enough to
accommodate only one lobe (usually a lower lobe) from
each donor. Reports from the University of Southern
California, where the procedure was pioneered, showed a
1, 3 and 5-year survival rate of 70%, 54% and 45%
respectively [47]. The average post-operative reduction in
the FEV1 and FVC for lobar donor organs (in comparison
to cadaveric lungs) is about 17% and 15%, respectively
[48].
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Complications of lung transplantation may arise in the
peri-operative time period and include bleeding, diaphrag-
matic paresis or paralysis, immediate graft failure, pulmo-
nary edema, anastomotic stenosis or dehiscence, renal
failure, stroke, and acute bacterial infection. Some patients
will require cardiopulmonary bypass at the time of
transplantation (Table 6). Because size matching is an issue
in transferring lungs from one thoracic cavity to another,
problems may arise from size discrepancy. Lungs too small
for the recipient may over-inflate leading to possible graft
dysfunction or pleural effusions, and those too large for the
recipient may develop atelectasis and pneumonia as well as
compromise hemodynamic status. Although size matching is
important, lung reduction is possible to optimize fit and has
no apparent ill-effects on graft survival or mortality.
All lung allografts develop some degree of reperfusion
injury that is characterized by inflammation and edema
[49]. Although mild pulmonary edema is usually present in
the immediate post-operative period, more severe pulmo-
nary edema may precede a multitude of complications.
Disrupted lymphatics or vascular anastomoses can con-
tribute to post-implantation edema, as can acute renal
failure, fluid overload and massive transfusions. Early graft
failure from severe reperfusion injury occurs as a
consequence of reestablished blood flow into newly
implanted lungs that have extensively damaged endothe-
lial–alveolar interfaces. Chatila et al. identified ischemia
reperfusion lung injury as a major contributor to early
respiratory failure and mortality in patients receiving lung
allografts [50]. Hyperacute graft rejection, which may
occur if preformed antibodies that recognize graft alloanti-
gens are present at the time of transplant, can also cause
early, severe graft dysfunction that has a devastating effect
on graft function. Primary graft failure has been shown to
occur in 13 to 25% of lung transplant recipients [51], and it
has an overwhelmingly negative effect on recovery causing
prolonged hospitalization and increased mortality [52].
Thabut et al. have reported an even higher incidence of
primary graft failure (50%) using criteria of radiographic
infiltrate in the first 3 days after transplant with PaO2:FiO2
b300 mm Hg, and they have identified a higher incidenceTable 6
Peri-operative findings for recipients with CF transplanted at UWHC
(N=57)
Use of cardiopulmonary bypass 36 (63.2%)
Use of nitric oxide 21 (36.8%)
Peri-operative deaths 2 (3.5%)
Significant hemorrhage 8 (14.4%)
Anastomotic dehiscence⁎ 8 (14.5%)
Diaphragm dysfunction⁎ 8 (14.5%)
Mean days to extubation⁎ 8.1±12.8
Mean days to hospital discharge⁎ 28.3±20.7
⁎N=55. Mean values reported with standard deviations.of ICU mortality in those with primary graft failure versus
those without (29% vs 10.9% respectively) [53]. This same
group recognized four variables that predict higher
mortality, age, degree of gas exchange impairment, graft
ischemia time, and severe early hemodynamic failure.
Post-operative administration of nitric oxide (NO) may
improve hemodynamics and gas exchange when severe
allograft dysfunction occurs in the early post-operative
period [54], and NO has been administered to one-third of
transplant recipients at UWHC to alleviate early allograft
dysfunction (Table 6). However, clinical efficacy of NO in
peri-operative management of lung transplant recipient has
not been clearly demonstrated [55].
Problems that may arise with bronchial anastamoses
include ischemia, dehiscence, ulcerations and stenosis. Pre-
operative steroid use, cardiopulmonary bypass, reperfusion
injury, acute rejection, airway infection and post-operative
cytolytic medications may predispose individuals to develop
anastomotic problems. Aspergillus infection of tracheobron-
chial anastomoses may occur, and patients with CF appear to
be especially susceptible to tracheobronchial aspergillosis,
perhaps because of their high pre-transplant likelihood of
colonization [35,36]. Bacterial or opportunistic fungal
infection is always a concern in the peri-operative period
and can arise from aspiration, contamination of surgical sites
or nosocomial infections.
3.1. Post-transplantation issues
3.1.1. Surveillance
In the early post-operative period, transplant recipients
require close and frequent evaluation to monitor for
rejection, graft dysfunction and infection. Because of the
high prevalence of five major complications — hyperlipid-
emia, diabetes mellitus, osteoporosis, renal insufficiency,
and systemic hypertension — in all transplant recipients,
screening for these complications should be done at
appropriate intervals in the post-transplant period. These
and other extrapulmonary problems such as hepatic
dysfunction, gastrointestinal complications, and paranasal
sinus disease must be managed intensively. Similarly, blood
levels of immunosuppressants, such as cyclosporine and
tacrolimus, should be frequently monitored to ensure
therapeutic levels and avoid drug toxicity (our protocol is
weekly following post-transplant hospital discharge until
stable, then biweekly until stable, then monthly until stable,
then bimonthly to quarterly if stable). Frequent clinic visits at
a CF center allow caregivers to evaluate nutritional status
and pulmonary status and to identify early complications
including medical and psychosocial problems. Daily mea-
surements of heart rate, blood pressure, temperature, and
spirometry should be obtained in the early post-operative
period to detect complications and intervene in a timely
fashion when problems are detected. Fever and significant
impairment in lung function (decrease in FEV1 N10% over
48 h) require immediate evaluation, and bronchoscopy with
Table 8
Post-transplant characteristics of recipients with CF transplanted at UWHC
and surviving the post-operative period (N=55)
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lavage (BAL) are usually necessary to establish an accurate
diagnosis.Table 7
Complications following lung transplantation
Peri-operative
Ischemia-perfusion injury
Early graft dysfunction
Hyperacute rejection
Hemorrhage
Multisystem failure
Central nervous system dysfunction
Pulmonary embolism
Anastamotic complications
Pneumonia
Pleural effusion
Emphysema
Tracheobronchial aspergillosis
Axillary vein thrombosis
Phrenic nerve injury
Vocal cord paralysis
Bowel complications
Impaired motility
Bezoar
Diverticulitis
Perforation
Colitis
Biliary tract dysfunction
Subacute complications
Acute cellular rejection
Infection
Bacterial
Viral
Fungal
Mycobacterial
Pneumocystis infection
Diabetes
New onset
Worsened control
Compression fractures
Delayed complications
Bronchiolitis obliterans
Infection
Tracheobronchitis
Pneumonia
Emphysema
Lymphoproliferative disease
Progressive renal failure
Diabetes mellitus
Osteoporosis
Hepatobiliary dysfunction
Other complications
Systemic hypertension
Cardiac rhythm disturbances
Neurotoxicity
Tremor
Hemolytic-uremic syndrome
Myopathy
Hypercoagulability
Myelosuppression
Avascular necrosis of bone
Hyperlipidemia
Malignancies
Menstrual irregularities
Acute rejection grade ≥A2 34 (61.8%)
Bronchiolitis obliterans syndrome (BOS) 17 (30.9%)
Mean time (months) to BOS (N=16⁎) 24.3±14.3
Total deaths 17
Deaths due to BOS 9
Aspergillus infection 23 (41.2%)
Bacterial pneumonia⁎⁎ 25 (45.5%)
P. aeruginosa pneumonia 17 (30.1%)
CMV infection 16 (29.1%)
Pneumocystis infection 2 (3.6%)
Mycobacterial infection 5 (9.1%)
Mean rise in creatinine at 1 year (N=49) 0.8±0.5 mg/dl
Hemodialysis 6 (10.7%)
Kidney transplantation 3
Lymphoproliferative disease 1
Gastrointestinal bezoar 10 (18.2%)
Clostridium difficile infection 5 (9.1%)
Liver disease 3 (5.5%)
Biliary disease 8 (14.5%)
Re-transplant 2
Mean FEV1% at 6–12 months (N=48) 85.4±24.1
Acute rejection graded A0–A4 (see Table 9). ⁎Time of onset of BOS
unknown for 1 patient. ⁎⁎Including P. aeruginosa pneumonia. Mean values
are reported with standard deviations.Transbronchial lung biopsy provides a relatively safe and
important tool for detection of rejection and infection. The
sensitivity and specificity of TBLB in identifying acute
rejection (AR) is 72% and 90–100%, respectively, and
TBLB has a sensitivity of 91% and specificity of 70% for
detecting CMV pneumonia [56]. Follow-up TBLBs should
be performed in patients with previous diagnoses of rejection
as they have been shown to provide valuable diagnostic
information in regards to infection and rejection [57].
Routine surveillance bronchoscopies with TBLB are per-
formed at many transplant centers because of the unexpect-
edly high rate of AR and CMV found histologically in
clinically stable patients [56,58]. At our institution, surveil-
lance bronchoscopies are usually performed at post-trans-
plant week 2, 6, 12, 18, 26, 40, and 52. These surveillance
bronchoscopies allow inspection of airways and anastamoses
as well as performing BAL and TBLB. Examination of BAL
fluid can be particularly helpful in identifying bacterial,
opportunistic, viral and fungal infections.
In addition to frequent spirometric testing to detect
allograft dysfunction including the onset of bronchiolitis
obliterans syndrome (BOS), thoracic computed tomography
(CT) scanning can help in detecting problems post-opera-
tively that may not be detected by routine chest X-ray and
other testing by providing better imaging to elucidate
problems. By using end-expiratory, thin-section CT scanning
in the post-operative period, changes suggestive of the onset
of bronchiolitis obliterans may be detected relatively early,
and these changes may be present when pulmonary function
measurements have not declined to values that are consistent
with the development of BOS. Studies have shown a
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67–94% when using air trapping as a marker for detec-
ting BOS and bronchiolitis obliterans [59,60]. Although
thoracic CT scanning can be useful, a clear-cut role for
its routine use has not been defined in the post-transplant
setting.
3.1.2. Immediate and long-term complications
Although the majority of complications following lung
transplant are dominated by infections and rejection, many
other complications (Table 7) may also occur. Rejection is a
major cause of allograft dysfunction and failure in both the
immediate time period following lung transplantation as well
as long-term. The majority of recipients transplanted at our
institution had Grade A2 or higher rejection episodes
(Table 8). Acute rejection is typically characterized by a
fall in FEV1 and may be accompanied by the onset of
malaise, cough, fever, leukocytosis, changes on chest
radiograph, and gastrointestinal complaints. However,
rejection can occur without a significant decline in FEV1,
changes on the chest radiograph, or other symptoms and may
only be detected via surveillance bronchoscopy with TBLB.
A diagnosis of acute rejection is based upon the detection of
perivascular and interstitial mononuclear cell infiltrates in
lung biopsy specimens using a commonly accepted grading
scale that was revised in 1996 (Table 9) [61,62]. The grading
system ranges from A0 to A4, and perivascular mononuclear
infiltrates are typically present in patients with acute rejec-
tion, although infection must be excluded when making the
diagnosis. Although grade A1 has been considered to be
clinically insignificant and quite commonly seen on sur-Table 9
Grading system for acute rejection [62]
Acute rejection Airway inflammation a
A0 (none): No inflammation,
hemorrhage, necrosis
B0 None: No inflammation
A1 Minimal: Scattered,
infrequent perivascular
mononuclear infiltrates.
B1 Minimal: Rare scattered
mononuclear cells in submucosa of
bronchi/bronchioles
A2 Mild: Frequent perivascular
mononuclear infiltrates.
B2 Mild: Circumferential band of
mononuclear cells in submucosa of
bronchi/bronchioles. Necrosis or
transepidermal migration of
lymphocytes.
A3 Moderate: Dense
perivascular
mononuclear
infiltrates, usually
with endothelialitis.
B3 Moderate: Dense band-like
infiltrate of mononuclear cells in
lamina propria of bronchi/bronchioles.
Necrosis and marked transepithelial
migration of lymphocytes.
A4 Severe: Dense perivascular,
interstitial and airspace
mononuclear infiltrates
associated with necrosis and
hemorrhage.
B4 Severe: Dense band-like infiltrate of
mononuclear cells in lamina propria of
bronchi/bronchioles. Dissociation of
lamina propria from basement
membrane, ulceration/necrosis of
epithelium, neutrophilic exudates.
BX Ungradeable
a Cases of acute rejection may be reported with classification of airway
inflammation.veillance TBLB performed after transplant, recent studies
suggest that grade A1 rejection is not completely benign and
may even warrant intervention [63,64]. Grade A2 or higher
requires more intensified immunosuppression and is usually
accompanied by worsening lung function and oxygenation.
Fortunately, acute rejection is usually responsive to high-
dose corticosteroids and rarely fatal. A follow-up TBLB
should be performed after the corticosteroid burst and other
changes in the immunosuppressive regimen to verify that the
rejection episode has been adequately treated. Unfortunately,
episodes of acute rejection, among other complications, have
been considered to be a major risk factor for developing
chronic rejection in the transplanted lung [65].
Acute rejection may also involve airways, and lymphocytic
bronchiolitis in this setting is thought to be a precursor of
chronic allograft rejection. Changes in airways are also graded
by severity and range from sparse lymphoid infiltrates around
airways to dense mononuclear cell infiltration with epithelial
damage and fibrin exudation. However, the significance of
airway changes (GradeNB0) in the absence of acute paren-
chymal rejection (Grade=A0) or allograft infection is unclear.
Additionally, airways may not be adequately sampled in TBLB
to allow identification and grading of airway inflammation.
Chronic rejection commonly complicates the post-
transplant course and manifests itself as bronchiolitis
obliterans (BO), which has been found to be present in at
least 50% of transplant recipients who have survived 5 years
or more following transplant [66]. Bronchiolitis obliterans
has been linked to numerous risk factors, typically has an
insidious onset, and rarely occurs before 6 months post-
transplant. Risk factors other than episodes of acute rejection
that have been linked to the development of BO via
multivariate analysis include CMV pneumonitis and HLA
mismatching [67]. One of the first clues to the presence of
BO is a decrease in small airways function (FEF 25–75%),
and the appearance of symptoms that resemble a CF
respiratory exacerbation. Tranbronchial biopsy has a disap-
pointingly low sensitivity of 17% for detecting BO [68]. This
low sensitivity led to the development of a system that uses
the surrogate marker of FEV1 as an indicator of the presence
of BO [62] when other explanations for sustained decline in
lung function have been excluded in patients who have
survived at least 3 months following transplantation. The
term BOS was coined to describe a sustained decrease in
FEV1 to a value that is less than 80% of the best post-
transplant value obtained once recipients had recovered from
the surgical procedure [61]. A staging system for BOS has
evolved that is based on the severity of decline in FEV1
rather than TBLB histopathologic findings, given the poor
sensitivity for TBLB in diagnosing BO. Because a threshold
of a 20% decline in FEV1 may be somewhat insensitive for
detecting the onset of BO, this staging system was revised in
2002 to include measurement of the FEF 25–75% and/or a
10% decline in FEV1 from the best post-transplant value as
indicators that would trigger suspicion for the onset of BO
[65].
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and significantly increases the risk of mortality for lung
transplant recipients. In our cohort of 55 CF patients who
survived the peri-operative period (more than 3 months), 17
(30.9%) have developed BOS, and the mean time to
development was 24.3 +/−14.3 months. Of the 17 CF patients
who have died in the post-transplant period, 9 (52.9%)
have died due to BOS. Transplant recipients who have
developed BO may have increased sputum production, grow
P. aeruginosa or other bacterial pathogens on sputum culture,
and show signs of bronchiectasis and end-expiratory air
trapping on chest CT. Treatment has traditionally consisted of
augmenting immunosuppression, but prognosis is relatively
poor once BO is clearly present. Data obtained by Swanson
et al. support the use of intensive induction immunosuppres-
sion and aggressive treatment of AR based on frequent
surveillance TBLB as a way of decreasing the risk of
developing chronic rejection [69]. Some patients with chronic
rejection may stabilize if their calcineurin inhibitor is switched
from cyclosporin to tacrolimus [70]. Azithromycin, which
has anti-inflammatory properties, has recently been identified
as a potential agent that stabilizes and may even reverse
lung function decline in recipients who have progressive BO
[71–73], and administration of statin therapy has also been
reported to be beneficial [74]. Recent investigations suggest an
important role for gastroesophageal reflux (GER) as a risk for
BOS [75], and GER, which is frequently asymptomatic, has
been identified as a pervasive finding in lung transplant
recipients with CF [76]. Because of its pervasiveness, GER
should be aggressively medically treated and if inadequately
treated with medications, surgery should be considered [76].
Recently published observations [77,78] as well as in data
from our lung transplant recipients (unpublished data) suggest
a role for cell-mediated immunity directed against collagen V
in small airways as a possible cause of BO.
Infection can occur at any time following transplantation.
Although patients with CF have persistence of bacterial
pathogens in paranasal sinuses and native airways, Flume et al.
[79] did not find a significantly increased risk for post-
operative infections in recipients with CF when compared to
patients receiving lung transplants for other indications. In our
cohort of CF recipients, three lung allograft infections occurred
at high frequency: Aspergillus (anastamosis site or otherwise)
infection (41.2%), CMV infection (29.1%) and P. aeruginosa
pneumonia (30.1%). Pneumocystis and non-tuberculous
mycobacterial lung infection also occurred in our CF cohort
with frequencies of 3.6% and 9.1%, respectively.We have also
observed significant allograft bronchiectasis in recipients who
do not appear to meet criteria for BOS. These areas of
bronchiectasis may provide an environment for bacterial
colonization and persistence, which, in the setting of intense
immunosuppresion, place the transplant recipient at high risk
for acute and chronic bacterial infection.
Cytomegalovirus (CMV) infection typically occurs later
in the post-operative period with peak risk at 1 to 3 months
post-transplant, and risk is increased if the donor or recipientis seropositive [80]. The risk of CMV infection and the
development of clinically severe disease is increased when a
seronegative recipient is infected post-transplant after having
received organs from a CMV positive donor [80]. Disease
severity seems to be reduced in seropositive recipients,
presumably from the development of pre-transplant immu-
nity. The lowest risk patients are those who are seronegative
and receive organs from seronegative donors. Other factors
that increase the likelihood of CMV disease in the
transplanted patient include blood transfusions, immuno-
suppressive induction regimens that deplete lymphocytes,
the presence of BOS, and co-infection with human Herpes
viruses 6 or 7 [81].
The development of rapid shell-vial culture techniques
and, more recently, polymerase chain reaction (PCR)
methods have greatly improved the ability to quickly
establish a clinical diagnosis of CMV infection. However,
it may be difficult to distinguish infection from disease.
CMV disease is a cytopathologic process with significant
organ involvement that may progress to significant dysfunc-
tion. The demonstration of inclusion bodies in CMV-infected
cells is pathognomonic for CMV disease involving the lung.
The presumptive diagnosis of CMV disease can frequently
be made on the basis of clinical features and positive culture
or PCR results. CMV disease may be treated with
intravenous (IV) ganciclovir or oral valganciclovir, the
prodrug. The effectiveness of ganciclovir has been estab-
lished, but ganciclovir may sometimes be cumbersome to
use because only the IV preparation appears to be effective
for treatment of disease. Valganciclovir is available in oral
preparations that have shown comparable blood levels to IV
ganciclovir [82,83], but data on its effectiveness and duration
of treatment are limited [84]. Those who do not respond to
treatment with antiviral therapy should be questioned about
their adherence to the regimen, or viral resistance should be
considered. Prolonged maintenance therapy may be needed
to prevent recurrence and CMV-specific or polyvalent
immune globulin may be used to augment the treatment
regimen in those with CMV disease.
Because of the significance of CMV disease, many
centers have taken either a universal or pre-emptive approach
to treat CMV infection early and prevent it from progressing
to CMV disease [85]. The universal approach employs anti-
viral therapy for all those who undergo lung transplantation.
This has the advantage of covering all those at risk but
disadvantages include drug toxicity, increased cost, and the
possibility of developing drug-resistant CMV. The pre-
emptive approach employs screening for CMVinfection, and
prophylaxis is initiated if CMV infection is detected. The
advantages of the pre-emptive approach include decreased
cost and toxicity, but disadvantages include the cost of
surveillance and the possibility that screening techniques
may fail to identify an evolving infection early enough for
therapy to be effective.
Prophylaxis, universal or pre-emptive, appears to have
reduced the incidence and severity of CMV disease
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and CMV immune globulin can be used as prophylactic
agents, but there is no consensus as to the optimal dose,
timing and duration of the regimen. A potential negative
consequence of a prophylactic approach may be the
emergence of resistant strains of CMV [87–89]. Further-
more, these agents can have significant toxic effects.
Ganciclovir may cause pancytopenia, nephroxicity, and
seizures. Nephrotoxicity is less common with valganciclovir,
but the dose must be adjusted for renal function. Pancyto-
penia is associated with valganciclovir use.
Other problems such as osteopenia, diabetes, gastrointes-
tinal complications and nutrition are common complications
in recipients with CF. Osteopenia is a major concern because
most recipients with CF already have significantly decreased
bone mineral density prior to receiving post-transplant
immunosuppressive therapy that is likely to accelerate
bone loss [90,91]. Strategies to monitor bone mineral density
and prevent bone loss are important aspects of post-
transplant management. Gastrointestinal complications,
especially distal intestinal obstruction syndrome (DIOS),
have been identified as a relatively common problem in a
recent retrospective review [92], and gastrointestinal bezoars
have occurred in many of our patients (18.2%) significantly
complicating post-transplant management.
A potentially devastating complication, post-transplant
lymphoproliferative disease (PTLD) seen in one of our
patients, is thought to be caused by T-cell suppression
combined with either EBV infection or chronic graft antigenic
stimulation. PTLD is characterized by unchecked B-cell
proliferation in the transplanted lung and usually occurs
within the first year. It may also be detected in extrapulmonary
sites, although usually at later time points. Patients who are
EBV seronegative seem to be at highest risk for developing
PTLD in the post-operative period [93]. Current treatment
approaches include decreasing the level of immunosuppres-
sion in order to re-establish the patient's immunity against
EBVand/or the use of rituximab [94] in cases where the B cell
population has the marker CD20. Patients unresponsive to
such measures may need to undergo chemotherapy. Surgical
resection or low dose radiation therapy are options in situations
where there is a single lesion or localized disease [95]. Overall,
the mortality attributed to PTLD is 37–50%.
4. Immunosuppression and allograft rejection
The post-transplant immunosuppressant regimen usually
consists of the combination of a calcineurin inhibitor
(cyclosporine A or tacrolimus), an inhibitor of purine
synthesis, and corticosteroid (Table 10). The calcineurin
inhibitors potently inhibit T-cell activation, and cyclosporine
A or tacrolimus are used as the “backbone” of the
immunosuppressive regimen. When acute rejection seems
to be refractory, tacrolimus has been shown to have greater
efficacy [96]. The purine synthesis inhibitors employed in
the immunosuppressive regimen are typically azathioprine ormycophenolate mofetil. Although smaller studies have
shown mycophenolate mofetil to have superior efficacy
over azathioprine in preventing rejection [97,98], a multi-
center trial did not demonstrate a significant difference in
survival or incidence, time to acquisition and severity of
BOS between the two drugs [99]. Recent interest surround-
ing the use of inhaled cyclosporine has arisen after a
publication by Iacono et al. [100]. This group found that, in
addition to systemic immunosuppression, inhaled cyclospor-
ine dosed three times a week when initiated in the first
6 weeks after lung transplantation improved survival and
prolonged survival free of chronic rejection when compared
to placebo. This method of immunosuppression is particu-
larly attractive because of the possibility of administering
high concentrations of cyclosporine to the lung without
adversely affecting renal function (see below). Finally,
prednisone is the corticosteroid of choice in most centers,
although methylprednisone is usually given in the early post-
operative period and is usually administered in high doses
for the initial treatment of acute rejection. Because of its
adverse effects, especially on blood sugar control and bone
mineral density, priority has been given in some centers to
significantly decreasing or discontinuing prednisone dosing.
The immunosuppressant regimen at our center consists of
induction therapy with a calcineurin inhibitor (cyclosporine
A or tacrolimus), anti-IL-2 (daclizumab), an antimetabolite
(azathioprine or mycophenolate), and corticosteroid. The
choices available for induction therapy with polyclonal or
monoclonal antibodies are antithymocyte globulin (ATG),
muromonab-CD3 (OKT3) or IL-2 receptor antagonists
(basiliximab or daclizumab). The most recent report from
the ISHLT shows that slightly less than 45% of adult lung
recipients have had induction immunosuppression with one
of these antibodies [3]. The IL-2 receptor antagonists are the
most commonly used. Opinions are mixed as to the
importance of these agents in immunosuppression induction
because of conflicting data about the efficacy in preventing
acute and chronic rejection as well as the risk of infection and
PTLD [101–105]. Data from the ISHLT demonstrate a
significant survival advantage for adults receiving induction
immunosuppression [3]. After induction, maintenance
therapy consists of cyclosporine A or tacrolimus, azathio-
prine or mycophenolate, and a corticosteroid. Sirolimus may
be added and the dosage of calcineurin inhibitor decreased if
significant renal dysfunction becomes a problem [106–108].
Currently employed immunosuppressive agents have great
potential to cause serious adverse events. Renal insufficiency
and failure are of great concern with cyclosporine and
tacrolimus. Ten percent of patients transplanted for CF at our
center have developed renal failure severe enough to require the
initiation of hemodialysis, and 5% of our patients have had
renal transplantation for late-onset renal failure. Medications
commonly used in CF such as azithromycin or other antibiotics
can alter clearance of such drugs, necessitating close
monitoring of blood immunosuppressant levels. Additionally,
underlying gastrointestinal and hepatic dysfunction that occurs
Table 10
Immunosuppressive agents used following lung transplantation
Agent Mechanism of action/target Major toxicities Common side effects
Cyclosporine Inhibits T lymphocyte
activation (suppresses IL-2 production)
Nephrotoxicity Tremor
Hypertension Headache
Hyperkalemia Hirsutism
Hypomagnesemia Pruritis
Pancreatitis Gastrointestinal motility disturbance
Seizure
Tacrolimus Inhibits T lymphocyte
activation (suppresses IL-2 production)
Nephrotoxicity Dermal erythema
Diabetes mellitus Gastrointestinal motility disturbance
Hypertension Tremor
Hyperkalemia Headache
Hypomagnesemia Insomnia
Sirolimus
(rapamycin)
Inhibits DNA and protein synthesis
(IL-2 signaling and T lymphocyte activation)
Hypertension Arthralgia
Dyslipidemia Headache
Pulmonary toxicity Anemia
Hepatotoxicity Thrombocytopenia
Pancytopenia
Mycophenolate
mofetil
Inhibits purine biosynthesis (lymphocyte activation) Myelosuppression
Gastrointestinal hemorrhage
Insomnia
Gastrointestinal motility disturbance
Corticosteroids Inhibit cytokine gene transcription and secretion Diabetes mellitus Fluid retention
Osteoporosis Cataracts
Myopathy Weight gain
Obesity
Azathioprine Inhibits purine biosynthesis (lymphocyte activation) Pancreatitis Gastritis
Bone marrow suppression
Antithymocyte
globulin
Lymphocyte depletion
(via T lymphocyte and MHC antigens)
Infection Gastrointestinal upset
Cardiovascular instability Fever
Hyperkalemia Myalgia
Capillary leak syndrome Headache
OKT3 Monoclonal
antibody
Lymphocyte depletion
(CD3 complex on T lymphocytes)
Infection Gastrointestinal upset
Capillary leak syndrome Headache, rigors
Vision disturbance Arthalgia, myalgia
Daclizumab IL-2 receptor binding
(inhibits IL-2-driven T lymphocyte proliferation)
Hypersensitivity reaction (rare) Fever
Basiliximab IL-2 receptor binding (inhibits
IL-2-driven T lymphocyte proliferation)
Hypersensitivity reaction (rare)
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and monitoring of immunosupressants, and patients with CF
display lower bioavailability and greater variability of blood
cyclosporine levels than recipients transplanted for other
indications [109]. The adverse effects of immunosuppressants
combined with the various pulmonary and extrapulmonary
complications of CF make management of the transplant
recipient with CF particularly challenging and warrant close
and frequent monitoring. Sirolimus for use in the transplant
patient with renal insufficiency or failure has been helpful,
however even this “renal protective” immunosuppressant has
its drawbacks. Sirolimus impairs bronchial anastamosis healing
leading to dehiscence of bronchial anastomoses, and it can also
precipitate interstitial pneumonitis [110–112].
4.1. Outcome and quality of life
Most patients experience improvements in gas exchange,
lung function, and exercise tolerance and are liberated from
daily, time-consuming sessions of inhalation therapies and
secretion clearance. Quality of life is also improved in most
lung transplant recipients despite the rigors of post-transplantsurveillance and morbidity that is associated with immuno-
suppression. Gas exchange usually improves to the point that
patients who were oxygen-dependent prior to the surgery
may be discharged to home without supplemental oxygen
and have normal oxyhemoglobin saturation maintained on a
six-minute walk test. Lung function has been demonstrated
to improve with mean FEV1 increasing from 20% to 80%
predicted and FVC increasing from 38% to 82% predicted
[113]. We have observed a mean increase in FEV1 values
from 24.8% prior to transplant to 85.4% at 1 year post-
transplant. Exercise tolerance improves greatly, allowing
most transplant recipients to perform activities of daily living
without limitation, although formal exercise testing re-
veals that maximum oxygen consumption remains limited
to 50–60% predicted at peak exercise [114,115].
Egan et al. [116] published long-term results of their 10 year
experience with 131 lung transplant procedures for 123
patients (114with bilateral sequential lung transplants and nine
with bilateral lower lobe transplants from living donors).
Survival at 1 year was 81%, 5 years was 59% and 10 years was
38%. Subset analysis identified individuals with B. cepacia
and lobar transplant to have poorer outcomes while
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on survival. Despite the poorer outcome with B. cepacia, this
center still recommended transplantation for those who are
colonized with the organism. Kaplan–Meier curves for
patients with CF who received lung transplantation at our
center (Fig. 1) did not show a significant effect of pre-
transplant mechanical ventilation on survival. Vermeulen et al.
[117] have looked at health-related quality of life (HRQL) in
those transplanted for CF in comparison to those transplanted
for other reasons. Those with CF were more likely to be
working or going to school prior to the transplantation and also
reported greater mobility and energy. Both groups (CF and
non-CF) reported significant improvement in HRQL up to
31 months after receiving a lung transplant. This remains the
most compelling argument for lung transplantation.
4.2. Pediatric lung transplantation
With earlier diagnosis and improved medical care for
children with CF, transplantation has become less of an issue
for children than adults. However, some children have lung
disease that progresses rapidly to the point where transplant
is a necessary option for improved survival and quality of
life. As previously mentioned, two thirds of all lung
transplants performed in the 11–17 age range are performed
for CF [3]. Contraindications to pediatric lung transplanta-
tion are similar to those in adults. Such contraindications
include malignancy within 2 years; progressive neuromus-
cular disorder; and major extrapulmonary disease such as
HIV, hepatitis B or C, and chronic liver, heart or renal failure.
Psychosocial issues of not only the child but their family, the
major support system, must be taken into consideration in the
pre-transplant evaluation [118].
In 1999, Aurora et al. [119] examined the question of
whether lung transplantation may improve survival in
children ages 4–19 with CF. Using life expectancy less
than 2 years and poor quality of life as criteria for lung
transplantation, they found a 69% reduction in risk of death
for those who had received transplant compared to those who
were still on the waiting list or died while on the list. In those
who were referred for transplantation, the mean FEV1 was
less than 30%. Robinson and Waltz suggested that referral
for transplant should be sooner for young patients with
FEV1% falling below 50% [12] and others have suggested
that a child with persistent FEV1% b40% should be referred
to a lung transplant center [119]. St. Louis Children's
Hospital published outcome data in 2002 on transplant for all
indications. Of the 207 lung transplantations performed on
190 children less than 18 years old, 89 were for cystic
fibrosis. One, three and five-year mortality for this group was
77%, 62% and 55%, respectively [120]. Overall, pediatric
patients transplanted for CF have fared worse than those
transplanted for other indications with the exception of those
with pulmonary hypertension.
With some exceptions, complications in the pediatric
population are similar to those in adults. Pediatric lungtransplant recipients appear to have a higher incidence of
pneumonia and acute rejection in the early post-operative
period when compared to their adult counterparts [121] and
so antibiotics targeting organisms cultured pre-transplant are
important in the peri-operative period. Acute rejection,
however, seems to be less prevalent in infants. Also, airway
obstruction at anastomoses is more prevalent in children
receiving lung transplants as compared adults [122].
Neurologic adverse events after transplantation also seem
to be more prevalent in the pediatric age group with a
reported incidence of 45%; seizures being the most frequent
complication [123]. Calcineurin inhibitors are believed to
cause cerebral ischemia by vasoconstriction of vessels
leading to seizure. Fortunately, this effect is not persistent
in most children, and seizures are usually self-limited in the
early post-operative period. Gastroesophageal reflux, even
asymptomatic reflux, is quite prevalent in children who have
undergone lung transplantation [124]. Because of the high
incidence, and the possibility that it may have a role in
promoting BO, pediatric patients who have undergone lung
transplantation should be treated medically and, if necessary,
surgically for reflux disease.
Pediatric CF patients appear to have a high incidence of
PTLD. When CF is the indication for transplant, the odds
ratio of developing PTLD in pediatric lung transplant
patients increases to 5.8, and PTLD has been linked to the
occurrence of two or more episodes of acute rejection in the
first 3 months [125]. As with adult recipients, children must
be monitored for hypertension, renal failure, osteoporosis,
hyperlipidemia, and diabetes. Similarly, BO is the major late
complication of lung transplantation and remains a signif-
icant challenge for pediatric lung transplantation. Major risk
factors for developing BO consisted of greater than two
episodes of acute rejection and greater than 180 min of graft
ischemia time, but younger children and those who have
received living lobar donations are less prone to developing
BO [126,127].
5. Summary and conclusion
Lung transplantation is the only therapeutic option that is
likely to improve survival and quality of life for patients with
CF who have advanced lung disease and progressive decline
in lung function. Caregivers should try to determine whether
patients meet criteria for lung transplantation and whether
they lack absolute contraindications for transplantation prior
to referral. Patients who are referred to a lung transplant
center must be thoroughly evaluated to determine whether
they should be listed for lung transplantation. Because the
newly adopted UNOS allocation scoring system is based on
severity of pulmonary dysfunction and the likelihood of
reasonably prolonged survival following transplantation, the
length of time that patients spend on the list is no longer a
factor in assigning priority for transplantation. The major
obstacles to long-term survival are peri-operative complica-
tions, opportunistic infection, acute rejection, and BO.
347J.E. Spahr et al. / Journal of Cystic Fibrosis 6 (2007) 334–350Surveillance bronchoscopy with BAL and TBLB plays an
important role in monitoring for infection and rejection, and
it is performed at our center at defined intervals during the
first year after transplant. Despite the potential complications
of lung transplantation, patients can have prolonged survival
and good quality of life, even when transplant is performed
while they are receiving mechanical ventilatory support.
Progress in our understanding of the cause(s) of BOmay lead
to significant improvement in long-term survival following
lung transplant for CF.
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